Skin patch T-cell Covid vaccine to be trialled in Switzerland
The new vaccine will be administered as a tiny skin patch bristling with micro-needles that release the shot within seconds.
Keystone / Alexandra Wey
A British biotech firm is set to start clinical trials in Switzerland of a skin patch vaccine against Covid-19 that uses T-cells and could offer longer-lasting immunity than existing vaccines.
This content was published on
2 minutes
The Guardian/swissinfo/sb
Español
es
Suiza someterá a prueba vacuna COVID en parche cutáneo
Emergex announcedExternal link on Monday that it had received the green light from the Swiss drugs regulator to carry out initial human trials in Lausanne, starting January 3, 2022.
The company’s easy-to-administer skin patch vaccine primes T-cells – a group of immune cells that can target and destroy virus-infected cells – to remove infected cells from the body quickly after infection, thus preventing viral replication and disease.
Robin Cohen, Emergex’s chief commercial officer, told The GuardianExternal link newspaper: “This is the first time a regulator has approved a Covid vaccine to go into clinical trials whose sole purpose is to generate a targeted T-cell response in the absence of an antibody response and those T-cells look for infected cells and kill them.”
Current Covid-19 vaccines mainly generate an antibody response that wanes over time, which means people need booster shots to maintain protection against the virus. The Emergex vaccine works differently, by killing infected cells quickly. This means it could offer longer-lasting immunity – possibly for decades – and could also be better at fighting virus mutations, said Cohen.
The trial will be conducted by Blaise Genton, a professor at the University of Lausanne’s centre for primary care and public health. He said: “This exciting new scientific approach to developing a vaccine against Sars-CoV-2 addresses the need to generate a T-cell response to elicit long-term immunity.”
In all, 26 people will receive a high and a low dose of its experimental Covid-19 vaccine. Interim results from the trial are expected in June.
More
More
Coronavirus: the situation in Switzerland
This content was published on
An overview of the latest Covid-related information in the Alpine nation.
Has your continent reached its peak or is there still potential for economic growth?
Some regions of the world are on an upward trajectory with the promise of a steadily improving future. Where do you live? And in which direction is your region or continent developing?
Switzerland must pay more than originally planned for US F-35 fighter jets
This content was published on
Switzerland has been unable to push through a fixed-price deal (CHF6 billion) with the United States for 36 new F-35 fighter jets.
This content was published on
A small two-seater plane crashed into Lake Geneva near Vevey on Tuesday afternoon. The two people on board were able to escape from the submerged aircraft without any injuries.
Swiss National Bank publishes new banknote designs
This content was published on
The Swiss National Bank (SNB) is working on a new series of banknotes on the theme of “Switzerland and its altitudes”. Twelve designs for the new series have been submitted and the public's opinion is now being sought.
US envoy meets Sudan army chief in Switzerland to discuss peace proposal
This content was published on
Sudan's army chief Abdel Fattah al-Burhan and US envoy for Africa Massad Boulos met in Switzerland to discuss a US peace plan aimed at ending the civil war in Sudan.
This content was published on
Late Shift [Heldin], a film by about overworked nurses, is Switzerland's candidate for the Best International Feature Film award at the Oscars next year.
US tariffs: most Swiss rule out making future concessions, survey reveals
This content was published on
According to a survey published on Wednesday, most Swiss residents are against offering concessions to the US in the current tariff dispute.
While Switzerland struggles to vaccinate, Portugal is already finished
This content was published on
Nowhere are more people vaccinated against Covid-19 than in Portugal, where 98% of over 25-year-olds have had both doses.
Vaccine alternative has limited impact on Covid campaign
This content was published on
The offer of a non-mRNA Covid vaccine in Switzerland has failed to speed up the government’s vaccination campaign, experts say.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.